Therapeutic advances in chronic hepatitis B

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Chronic hepatitis B (CHB) is a significant global health concern.
• Lamivudine is a widely used antiviral medication for CHB treatment.
• Understanding treatment efficacy and resistance, like the YMDD variant, is crucial.

Purpose of the Study:

• To evaluate the long-term efficacy and safety of lamivudine in CHB patients.
• To assess the impact of YMDD-variant development on treatment outcomes.
• To investigate the effectiveness of combination therapy in decompensated CHB.

Main Methods:

• Analysis of patient data from lamivudine treatment cohorts.
• Monitoring of alanine aminotransferase (ALT) levels and seroconversion rates.
• Assessment of YMDD-variant incidence and its clinical implications.
• Evaluation of combination therapy with adefovir dipivoxil in specific patient groups.

Main Results:

• Lamivudine controlled CHB in most patients, with good response in those with elevated ALT.
• YMDD-variant incidence increased with treatment duration, but patients still benefited from continued lamivudine.
• Lamivudine demonstrated efficacy in HBeAg-negative and decompensated cirrhosis patients.
• Long-term lamivudine use was well-tolerated, with no increased serious adverse events in YMDD-variant patients.
• Combination therapy with adefovir dipivoxil showed significant efficacy and clinical improvements in decompensated CHB within 24 weeks.

Conclusions:

• Lamivudine is an effective and well-tolerated treatment for CHB, offering clinical benefits even with YMDD-variant.
• Combination therapy with adefovir dipivoxil provides significant efficacy for decompensated CHB.
• Continued lamivudine therapy is beneficial for patients developing YMDD-variant HBV.